检索结果-南通市图书馆

World Journal of Hepatology 2017年第6期9卷 333-342页

作者： Sirio Fiorino Maria Letizia Bacchi-Reggiani Paolo Leandri elisabetta loggi Pietro Andreone Unità Operativa di Medicina Interna C Ospedale Maggiore Unità Operativa Malattie Cardiovascolari Azienda Ospedaliero Universitaria di BolognaPoliclinico Sant’Orsola-Malpighi Dipartimento di Scienze Mediche e Chirurgiche Azienda Ospedaliero Universitaria di BolognaPoliclinico Sant’Orsola-Malpighi

AIM To assess vitamin E efficacy,defined as its ability to induce hepatitis B e antigen(HBeAg) seroconversion,in children with HBeAg-positive persistent *** In July 2016,we extracted articles published in MEDLINE and the Cochrane Library using the following search terms:"chronic hepatitis B","children","childhood","therapy","treatment","vitamin E","tocopherols","tocotrienols".Only randomized controlled trials(RCTs) published in English language were *** Three RCTs met inclusion criteria and were considered in the present ***,23/122 children in the treatment group underwent HBeAg seroconversion vs 3/74 in the control group(OR=3.96,95%CI:1.18-13.25,P=0.025).CONCLUSION Although our meta-analysis has several limits,including the very small number of available studies and enrolled children with HBeAg positivity-related hepatitis,it suggests that vitamin E use may enhance the probability to induce HBeAg seroconversion in these *** well designed and adequately sized trials are required to confirm or deny these very preliminary results.

关键词：肝炎 B 小儿科的 hepatology 病毒的肝炎免疫学

Ketoprofen,peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C:A phaseⅡ study

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2009年第47期15卷 5946-5952页

作者： Annagiulia Gramenzi Carmela Cursaro Marzia Margotti Clara Balsano Alessandra Spaziani Simona Anticoli elisabetta loggi Maddalena Salerno Silvia Galli Giuliano Furlini Mauro Bernardi Pietro Andreone Department of Clinical Medicine University of Bologna40138 Bologna Italy Molecular Virology and Oncology Laboratory "A.Cesalpino" FoundationUniversity of Rome"La Sapienza"00161 Rome Italy Department of Internal Medicine University of L'Aquila67100 L'AquilaItaly Hepatology Outpatient Clinic Hospital of Paola87027 Paola(CS)Italy Department of Hematology Oncology and Laboratory MedicineS.Orsola-Malpighi Hospital40138 BolognaItaly

AIM:To evaluate the safety of adding ketoprofen to pegylated-interferon(PEG-IFN)with or without ribavirin and the effect on viral kinetics,STAT1 activity and expression of 2'-5'-oligoadenylate synthetase (2'-5'OAS)in genotype 1 chronic hepatitis C in a phaseⅡstudy. METHODS:Forty-five patients were studied:fifteen were randomized to PEG-IFN plus ribavirin(PR),16 to PEGIFN plus ketoprofen and 14 to PR and *** study of IFN-dependent signal transduction was conducted in 9 patients from each group. RESULTS:The combination of ketoprofen and PEG- IFN with or without ribavirin was safe and well *** early activation of STAT1 was observed in ke-toprofen-treated patients,but this activation was less sustained over ***,ketoprofen plus PEG- IFN and ribavirin induced an early and sustained increase of 2'-5'OAS transcription starting 24 h after the first dose until the 36th *** data are consistent with the clinical results,showing a better sustained virological response and a lower relapse rate in patients receiving ketoprofen plus PEG-IFN and ribavirin. CONCLUSION:The addition of ketoprofen to the standard therapy of chronic hepatitis C should be explored in larger randomized clinical studies.

关键词：聚乙二醇化利巴韦林丙型肝炎干扰素酮洛芬基因型慢性信号转导

Liver grafts from hepatitis B surface antigen-positive donors: A review of the literature

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2016年第35期22卷 8010-8016页

作者： elisabetta loggi Fabio Conti Alessandro Cucchetti Giorgio Ercolani Antonio Daniele Pinna Pietro Andreone Dipartimento di Scienze Mediche e Chirurgiche Università degli Studi di Bologna Centro di Ricerca per lo Studio delle Epatiti Università degli Studi di Bologna

The scarcity of available organs and the gap between supply and demand continue to be the main limitations of liver transplantation. To relieve the organ shortage, current transplant strategies have implemented extended criteria, which include the use of liver from patients with signs of past or present hepatitis B virus(HBV) infection. While the use of liver grafts from donors with evidence of past HBV infection is quite limited, some data have been collected regarding the feasibility of transplanting a liver graft from a hepatitis B surface antigen(HBs Ag) positive donor. The aim of the present work was to review the literature regarding liver transplants from HBs Ag-positive donors. A total of 17 studies were identified by a search in Medline. To date, HBs Ag positive grafts have preferentially been allocated to HBs Ag positive recipients. The large majority of these patients continue to be HBs Ag positive despite the use of immunoglobulin, and infection prevention can only be guaranteed by using antiviral prophylaxis. Although serological persistence is evident, no significant HBV-related disease has been observed, except in patients coinfected with delta virus. Consistently less data are available for HBs Ag negative recipients, although they are mostly promising. HBs Agpositive grafts could be an additional organ source for liver transplantation, provided that the risk of reinfection/reactivation is properly prevented.

关键词：肝移植肝炎 B 边缘的接枝肝炎 B 积极接枝肝炎 B 表面抗原积极施主

Serum SCCA-IgM as a predictor of hepatocellular carcinoma in patients with liver cirrhosis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Open Journal of Gastroenterology 2012年第2期2卷 56-61页

作者： Daniela Buccione Gianluca Fatti Andrea Gallotta elisabetta loggi Roberto Di Donato Lilia Testa Carlo Saitta Valentina Santi Antonio Di Micoli Virginia Erroi Marta Frigerio Valentina Fazio Antonino Picciotto Alessandra Biasiolo Francoise Degos Patrizia Pontisso Giovanni Raimondo Franco Trevisani APHP Hopital Beaujon INSERM U 773 Clichy France Dipartimento di Medicina Clinica e Sperimentale “G. Patrassi” Università di Padova Padova Italia Dipartimento di Medicina Clinica Alma Mater Studiorum-Università di Bologna Bologna Italia Dipartimento di Medicina Interna Policlinico Universitario di Messina Messina Italia Dipartimento di Medicina Interna Università di Genova Genova Italia Xeptagen S.p.A. Venezia Italia

Aberrant Squamous Cell Carcinoma Antigen (SCCA) expression is an early hepatocarcinogenetic event and circulating SCCA-IgM complexes are elevated in most HCC patients. We evaluated whether serum SCCA-IgM levels can identify HCV +ve cirrhotic patients at low HCC risk. In this retrospective study we enrolled 29 cirrhotic patients in whom serum SCCA-IgM was measured 8 - 69 months (median 31) before HCC diagnosis, and 28 cirrhotic patients who remained HCC- free, with SCCA-IgM measured 15 - 68 months (median 48) before the study end. The best discriminating value of SCCA-IgM was calculated and tested in predicting HCC diagnosis within 12, 24 and 36 months. Sensitivity analysis, considering different HCC incidence, was conducted to identify the patient subgroup with an annual cancer risk below the threshold of a cost-effective semiannual surveillance with ultrasound. Cumulative HCC incidence at 12, 24 and 36 months was 7.0%, 15.7% and 26.3%, respectively. SCCA-IgM levels were higher in HCC than in cirrhotic patients [median: 381 (95% C.I.: 50 - 5289) vs. 100 (70 - 493) AU/mL, P = 0.005]. The SCCA-IgM value ≤ 200 AU/mL accurately identified patients at low risk of HCC development in the subsequent year (sensitivity 75%, specificity 62%, positive predictive value 13% and negative predictive value 97%). Considering an annual HCC incidence ≤ 3%, patients with SCCA-IgM ≤ 200 AU/mL (60% of the whole patients) had an HCC risk below the accepted threshold of a cost-effective surveillance (1.5%). In conclusion, provided that our provocative results are confirmed in larger studies, SCCA-IgM serum measurement could permit implementation of a two step (with different costs) surveillance: an initial serological surveillance, based on the annual monitoring of this biomarker, and the conventional surveillance by semiannual US when SCCA-IgM becomes >200 AU/mL. This could improve the cost/effectiveness of surveillance of HCV infected patients at risk of HCC.

关键词： SCCA-IgM HCC Risk Assessment Surveillance Cost/Effectiveness